255 related articles for article (PubMed ID: 28573325)
1. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
3. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas.
Sarkar S; Chacko AG; Chacko G
J Clin Neurosci; 2015 Jul; 22(7):1173-7. PubMed ID: 25979255
[TBL] [Abstract][Full Text] [Related]
5. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
6. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
8. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
9. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
10. Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling.
Madsen H; Borges TM; Knox AJ; Michaelis KA; Xu M; Lillehei KO; Wierman ME; Kleinschmidt-DeMasters BK
Am J Surg Pathol; 2011 Aug; 35(8):1204-13. PubMed ID: 21753697
[TBL] [Abstract][Full Text] [Related]
11. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
12. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
Hentschel SJ; McCutcheon lE; Moore W; Durity FA
Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
[TBL] [Abstract][Full Text] [Related]
13. Impact of ultra-low-field intraoperative magnetic resonance imaging on extent of resection and frequency of tumor recurrence in 104 surgically treated nonfunctioning pituitary adenomas.
Hlavica M; Bellut D; Lemm D; Schmid C; Bernays RL
World Neurosurg; 2013 Jan; 79(1):99-109. PubMed ID: 23043996
[TBL] [Abstract][Full Text] [Related]
14. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
15. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
16. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
17. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
[TBL] [Abstract][Full Text] [Related]
18. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
19. Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours.
Ebrahimi A; Schittenhelm J; Honegger J; Schluesener HJ
J Neuroendocrinol; 2011 Jun; 23(6):525-30. PubMed ID: 21453398
[TBL] [Abstract][Full Text] [Related]
20. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
